ArticleInternational journal of clinical and experimental pathology2018
The mechanism of quercetin in regulating osteoclast activation and the PAR2/TRPV1 signaling pathway in the treatment of bone cancer pain.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Mechanisms and traditional Chinese medicine therapeutics for primary osteoporosis: an integrated perspective.Frontiers in endocrinology · 2025Pooled it
- The Adjunctive Effect of Quercetin on Postoperative Pain Management Following Cesarean Section: A Randomized Controlled Study.Drug design, development and therapy · 2025Trial
- From multi-target mechanisms to clinical translation: the analgesic potential of quercetin.Frontiers in pharmacology · 2026Review
- A Quercetin/Rg3-Loaded Calcium Phosphate Nanoplatform Alleviates Breast Cancer-Induced Peripheral Hyperalgesia and Enhances Antitumor Immunity.International journal of nanomedicine · 2026Article
- Pharmacological Management of Cancer Pain: Advances in Treatment Strategies and Drug Delivery Systems.Pharmaceutics · 2025Review
- Tetrahydropalmatine has analgesic role in mouse model of bone cancer pain by inactivating the TNF-α/uPA/PAR2/TRPV1 pathway in dorsal root ganglia.Cancer cell international · 2025Article
- Health Benefits and Food Applications of Bioactive Constituents From Different Medicinal Parts (Bark, Leaf, and Fruit) ofFood science & nutrition · 2025Review
- Role of TRP Channels in Cancer-Induced Bone Pain.International journal of molecular sciences · 2025Review
- TRP channels and breast cancer: the role of TRPs in the pathophysiological development.Frontiers in molecular biosciences · 2025Review
- Liu-Shen-Wan inhibits PI3K/Akt and TRPV1 signaling alleviating bone cancer pain in rats.Cancer biology & therapy · 2024Article
- Therapeutic Potential of Quercetin as an Antioxidant for Bone-Muscle-Tendon Regeneration and Aging.Aging and disease · 2024Review
- Transient Receptor Potential Ankyrin 1 (TRPA1) Mediated LPS-Induced Inflammation in Periodontal Ligament Stem Cells by Inhibiting the Phosphorylation of JNK.Stem cells international · 2024Article
- Exploring the molecular mechanism of Xuebifang in the treatment of diabetic peripheral neuropathy based on bioinformatics and network pharmacology.Frontiers in endocrinology · 2024Article
- Pharmacological and mechanistic aspects of quercetin in osteoporosis.Frontiers in pharmacology · 2024Review
- Total Flavonoids Isolated from the Leaves ofCurrent pharmaceutical design · 2024Article
- Bioactivity, Molecular Mechanism, and Targeted Delivery of Flavonoids for Bone Loss.Nutrients · 2023Review
- The Emerging Role of Quercetin in the Treatment of Chronic Pain.Current neuropharmacology · 2022Review
- TRPV1 in dorsal root ganglion contributed to bone cancer pain.Frontiers in pain research (Lausanne, Switzerland) · 2022Review
- Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19.International archives of allergy and immunology · 2021Review
- Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies.Clinical and translational allergy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe present paper aimed to investigate the therapeutic effect of quercetin in a rat model of bone cancer pain, and to further explore the molecular mechanism of quercetin in the treatment of bone cancer pain.
methodsThe activation status of the osteoblasts in each group of rats was detected by anti-tartaric acid phosphatase (TRAP) immunohistochemistry, while the activation status of the osteoclasts was detected by alkaline phosphatase (BAP) immunohistochemistry. An ELISA assay was used to detect the levels of serum type I collagen carboxy-terminal pro-peptide (CDC), tartrate-resistant acid phosphatase (TRAP5b), and osteocalcin in each group, as well as the expressions of the main inflammatory mediator membrane protease (trypsin), TNF-α, and IL-1β in the PAR2/TRPV1 pathway in serum. Taking CD68 as a marker, immunohistochemistry was used to detect the positive proportion of macrophages in the left tibia of each group. Western blot was applied to analyze the expressions of the RANKL, OPG, RANK, PTHrP and IGF-1 proteins in rat bone tissue, the inflammatory mediators IL-8, M-CSF and TNF-α, and the PAR2/TRPV1 pathway-related molecules PAR2, TRPV1, PKC-Y and PKA in rat DRG neurons, as well as the neurotransmitters c-Fos, GFAP, PKR, and CGRP in the spinal cord.
resultsQuercetin significantly reduces serum CTX, TRAP and osteocalcin expressions in a rat model of bone cancer pain and also significantly reduces the proportion of TRAP-positive cells. The drug can significantly reduce the positive proportion of local bone tissue macrophages in rats with bone cancer pain. It can significantly decrease the expressions of RANKL, RANK, PTHrP and IGF-1 proteins and the inflammatory mediators such as IL-8, M-CSF and TNF-α, significantly increase the expressions of OPG and further significantly inhibit the expressions of the PAR2/TRPV1 pathway-related molecules PAR2, TRPV1, PKC-γ and PKA in DRG neurons, as well as significantly reduce the levels of major inflammatory mediators (trypsin), TNF-α, and IL-1β in the PAR2/TRPV1 pathway.
conclusionQuercetin can inhibit osteoclast activation and reduce bone destruction in the bone cancer pain model by regulating the RANKL/RANK/OPG signaling pathway and the inflammatory response. It can inhibit peripheral sensitization and central sensitization in bone cancer pain by regulating the PAR2/TRPV1 signaling pathway.
Indexed as
Identifiers
31949595PMC6963045W3010863040What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.